OTCQB: PHRRF | CSE: PHRM
PharmaTher Holdings Ltd. Ketamine
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT

News

3/24/2021

PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine

 

Read More

3/16/2021

World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor

 

Read More

3/2/2021

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig's Disease

 

Read More

3/1/2021

Newscope Announces DTC Eligibility of Its Common Shares in the United States

 

Read More

    Archives

    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020

    Categories

    All

    RSS Feed

Psychedelic Pharmaceuticals

COMPANY  /  RESEARCH  /  INVESTORS  /  NEWS  /  CONTACT
Publicly-traded on the OTCQB: PHRRF and CSE: PHRM
© COPYRIGHT 2022.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.